Collplant Biotechnologies Ltd
NASDAQ:CLGN

Watchlist Manager
Collplant Biotechnologies Ltd Logo
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Watchlist
Price: 2.01 USD -4.29% Market Closed
Market Cap: 25.6m USD
Section:
 

Relative Value

The Relative Value of one CLGN stock under the Base Case scenario is hidden USD. Compared to the current market price of 2.01 USD, Collplant Biotechnologies Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CLGN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

10.4
P/S
P/S
Price to Sales
10.4
vs History
71
vs Industry
19
Median 3Y
13.1
Median 5Y
19.4
Industry
7.9
Forward
2.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-3.5
Median 5Y
-6.2
Industry
24
Forward
-6.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-5.9
Industry
21.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-5.3
Industry
23.7
More Details
2.8
P/B
P/B
Price to Book Value
2.8
vs History
49
vs Industry
40
Median 3Y
2.7
Median 5Y
2.8
Industry
3.4
More Details
6.9
EV/S
EV/S
Enterprise Value to Sales
6.9
vs History
71
vs Industry
22
Median 3Y
9.1
Median 5Y
18.8
Industry
8.3
Forward
1.9
More Details
11
EV/GP
EV/GP
Enterprise Value to Gross Profit
11
vs History
44
vs Industry
60
Median 3Y
4.4
Median 5Y
5.9
Industry
10.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-4.3
Industry
6.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-4
Industry
7.2
Forward
-2.4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
-3.9
Industry
8.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-3.5
Median 5Y
-3.5
Industry
6.7
More Details
4.6
EV/IC
EV/IC
Enterprise Value to IC
4.6
vs History
85
vs Industry
34
Median 3Y
6.3
Median 5Y
7.8
Industry
5.7
More Details

Multiples Across Competitors

CLGN Competitors Multiples
Collplant Biotechnologies Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IL
Collplant Biotechnologies Ltd
NASDAQ:CLGN
25.7m USD 10.4 -2.1 -1.5 -1.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 071 784.8 -161 938.1 -196 644.6 -194 400.6
US
Abbvie Inc
NYSE:ABBV
394.9B USD 6.6 168.2 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
173.1B USD 4.8 24.7 17.9 17.9
US
Gilead Sciences Inc
NASDAQ:GILD
149.9B USD 5.2 18.5 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.9B USD 9.5 30.5 22.3 23.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.7 -527.6 -574.5 -559.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
74.4B USD 5.2 16.3 15.4 17.5
AU
CSL Ltd
ASX:CSL
89.8B AUD 3.8 19.9 13.3 16.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
56.9B USD 17.7 1 306.2 172 208.6
NL
argenx SE
XBRU:ARGX
47.9B EUR 15.5 36.4 63.1 64.9
P/E Multiple
Earnings Growth PEG
IL
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Average P/E: 202.6
Negative Multiple: -2.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 938.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.7
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
9%
1.8
AU
CSL Ltd
ASX:CSL
19.9
11%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 306.2
N/A N/A
NL
argenx SE
XBRU:ARGX
36.4
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IL
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Average EV/EBITDA: 41.6
Negative Multiple: -1.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 644.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.9
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
11%
1.4
AU
CSL Ltd
ASX:CSL
13.3
8%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
172
N/A N/A
NL
argenx SE
XBRU:ARGX
63.1
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IL
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Average EV/EBIT: 48
Negative Multiple: -1.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 400.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.9
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
13%
1.3
AU
CSL Ltd
ASX:CSL
16.6
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
208.6
N/A N/A
NL
argenx SE
XBRU:ARGX
64.9
N/A N/A

See Also

Summary
CLGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
CLGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CLGN stock valuation using valuation multiples.
Wall Street Estimates
CLGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CLGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.